,,ii  #aah? ,,congress  #a/ ,session    
,s4 #aac  ,,9 ,,! ,,s5ate ,,( ,,!       
,,unit$ ,,/ates  ,janu>y #bf1 #bjbc,mr4 
,grassley 7= himself1 ,ms4 ,cantwell1   
,mr4 ,blum5?al1 ,mr4 ,lank=d1 ,mrs4     
,blackburn1 ,mr4 ,tub]ville1 ,mr4       
,tillis1 ,mrs4 ,capito1 & ,mr4 ,braun7  
introduc$ ! foll[+ bill2 :i* 0 read     
twice & ref]r$ to ! ,committee on !     
,judici>y  ,a ,,bill  ,to require !     
,f$]al ,trade ,commission to /udy ! role
 ( int]m$i>ies 9 ! ph>maceutical supply 
*a9 & provide ,congress ) appropriate   
policy recomm5dations1 & = o!r purposes4
  #a4 ,%ort title ,?is ,act may be cit$ 
z ! ,prescription ,pric+ = ! ,p ,act (  
#bjbc4  #b4 ,def9itions ,9 ?is ,act3    
7#a7 ,appropriate committees ( congress 
,! t]m appropriate committees (         
,congress means-- 7,a7 ! ,committee on !
 ,judici>y ( ! ,s5ate2 &  7,b7 !        
,committee on ! ,judici>y ( ! ,h\se (   
,repres5tatives4  7#b7 ,commission ,!   
t]m ,commission means ! ,f$]al ,trade   
,commission4  #c4 ,/udy ( ph>maceutical 

supply *a9 int]m$i>ies & m]g] activity  
7a7 ,report ,n lat] ?an #a ye> aft] !   
date ( enactm5t ( ?is ,act1 !           
,commission %all submit to ! appropriate
 committees ( ,congress a report t--    
7#a7 addresses at m9imum-- 7,a7 :e!r    
ph>macy b5efit manag]s-- 7i7 *>ge pay]s 
a high] price ?an ! reimbursem5t rate at
 :i* ! ph>macy b5efit manag]s reimburse 
ph>macies own$ by ! ph>macy b5efit      
manag] & ph>macies n own$ by ! ph>macy  
b5efit manag]2  7ii7 /e] pati5ts =      
competitive advantage to any ph>macy1   
includ+ a retail1 mail-ord]1 or any o!r 
type ( ph>macy1 9 :i* ! ph>macy b5efit  
manag]s h an own]%ip int]e/2  7iii7     
audit or review propriet>y data1 includ+
 acquisition co/s1 pati5t in=mation1 or 
disp5s+ in=mation1 ( ph>macies n own$ by
 ! ph>macy b5efit manag] & use su*      
propriet>y data to increase rev5ue or   
m>ket %>e = competitive advantage2 or   
7iv7 use =mul>y designs to increase !   
m>ket %>e ( high] co/ prescription drugs
 or depress ! m>ket %>e ( l[] co/       

prescription drugs 7ea* net ( rebates & 
disc\nts72  7,b7 tr5ds or obs]vations on
 ! /ate ( competition 9 ! heal?c>e      
supply *a91 p>ticul>ly ) reg>d to       
int]m$i>ies & _! integration ) o!r      
int]m$i>ies1 suppli]s1 or pay]s (       
prescription drug b5efits2  7,c7 h[     
companies & pay]s assess ! b5efits1     
co/s1 & risks ( contract+ ) int]m$i>ies1
 includ+ ph>macy s]vices adm9i/rative   
organizations1 & :e!r m in=mation ab\t !
 roles ( int]m$i>ies %\ld be available  
to consum]s & pay]s2 &  7,d7 :e!r !re   
are any specific legal or regulatory    
ob/acles ! ,commission curr5tly faces 9 
en=c+ ! antitru/ & consum] protection   
laws 9 ! ph>maceutical supply *a91      
includ+ ! ph>macy b5efit manag]         
m>ketplace & ph>macy s]vices            
adm9i/rative organizations2 &  7#b7     
provides-- 7,a7 obs]vations or          
conclusions drawn f ! ,novemb] #bjag    
r\ndtable entitl$ ,und]/&+ ,competition 
9 ,prescription ,drug ,m>kets3 ,entry & 
,supply ,*a9 ,dynamics & any simil>     

ef=ts2  7,b7 specific actions !         
,commission int5ds to take z a result ( 
! ,novemb] #bjag r\ndtable1 & any simil>
 ef=ts1 includ+ a detail$ description ( 
relevant =?com+ actions1 additional     
rese>* or r\ndtable discussions1 consum]
 education ef=ts1 or en=cem5t actions2 &
  7,c7 policy or legislative            
recomm5dations to-- 7i7 improve         
transp>5cy & competition 9 !            
ph>maceutical supply *a92  7ii7 prev5t &
 det] anticompetitive behavior 9 !      
ph>maceutical supply *a92 &  7iii7 be/  
ensure t consum]s b5efit f any co/ sav+s
 or effici5cies t may result f m]g]s &  
consolidations4  7b7 ,int]im report ,n  
lat] ?an #ahj days aft] ! date (        
enactm5t ( ?is ,act1 ! ,commission %all 
submit to ! appropriate committees (    
,congress an int]im report on ! progress
 ( ! report requir$ by subsection 7a71  
along ) prelim9>y f9d+s & conclusions   
bas$ on in=mation collect$ to t date4   
#d4 ,report ,! ,commission %all submit  
to ! appropriate committees ( ,congress 

a report t includes-- 7#a7 ! numb] &    
nature ( compla9ts receiv$ by !         
,commission relat+ to an allegation (   
anticompetitive conduct by a manufactur]
 ( a sole-s\rce drug2  7#b7 ! ability ( 
! ,commission to br+ an en=cem5t action 
aga9/ a manufactur] ( a sole-s\rce drug2
 &  7#c7 policy or legislative          
recomm5dations to /r5g!n en=cem5t       
actions relat+ to anticompetitive       
behavior4